In vivo characterization of recombinant von willebrand factor in dogs with von Willebrand disease

Blood

Volumn 90, Issue 9, 1997, Pages 3555-3567

  Turecek, Peter L ^b   Gritsch, Herbert ^b   Pichler, Ludwig ^b   Auer, Wilfried ^b   Fischer, Bernhard ^b   Mitterer, Artur ^b   Mundt, Wolfgang ^b   Schlokat, Uwe ^b   Dorner, Friedrich ^b   Brinkman, Herm Jan M ^b   Van Mourik, Jan A ^b   Schwarz, Hans Peter ^a  

^a BAXTER HEALTHCARE CORPORATION   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; POLYMER; RECOMBINANT VON WILLEBRAND FACTOR; RISTOCETIN; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

AGAR GEL ELECTROPHORESIS; ANIMAL MODEL; ARTICLE; BLEEDING TIME; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DOG; DRUG HALF LIFE; EPISTAXIS; INTRAVENOUS DRUG ADMINISTRATION; MICROSCOPY; NONHUMAN; PRIORITY JOURNAL; VON WILLEBRAND DISEASE;

EID: 0030736701     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v90.9.3555     Document Type: Article

References (45)

1. Sadler JE: A revised classification of von Willebrand disease. Thromb Haemost 71:520, 1994
2. Ginsburg D, Sadler JE: Von Willebrand disease: A database of point mutations, insertions, and deletions. Thromb Haemost 69:177, 1993
3. Sadler JE, Davie EW: Hemophilia A, hemophilia B, and von Willebrand disease, in Stamatoyannopoulos G, Nienhuis AW, Majerus PW, Varmus H (eds): The Molecular Basis of Blood Diseases, (ed 2). Philadelphia, PA, Saunders, 1995, p 657
4. Montgomery RR, Coller BS: Von Willebrand disease, in Colman RW, Hirsh J, Marder VJ, Salzman EW (eds): Hemostasis and Thrombosis: Basic Principles and Clinical Practice (ed 3). Philadelphia, PA, Lippincott, 1994, p 134
5. Weiss HJ, Sussman II, Hoyer LW: Stabilization of factor VIII in plasma by the von Willebrand factor. J Clin Invest 60:390, 1977
6. Koppelman SJ, van Hoeij M, Lankhof H, Schiphorst ME, Damas C, Vlot AJ, Wise R, Bouma BN, Sixma JJ: Requirements of von Willebrand factor to protect factor VIII from inactivation by activated protein C. Blood 87:2292, 1996
7. Ruggeri ZM, Ware J: Von Willebrand factor. FASEB J 7:308, 1993
8. Lethagen S: Pathogenesis, clinical picture and treatment of von Willebrand's disease. Ann Med 27:641, 1995
9. Scott JP, Montgomery RR: Therapy of von Willebrand disease. Semin Thromb Hemost 19:37, 1993
10. Fischer BE, Schlokat U, Mitterer A, Reiter M, Mundt W, Turecek PL, Schwarz HP, Dorner F: Structural analysis of recombinant von Willebrand factor produced at industrial scale fermentation of transformed CHO cells co-expressing recombinant furin. FEBS Lett 375:259, 1995
11. Schlokat U, Fischer B, Mitterer A, Falkner F, Reiter M, Grillberger L, Mundt W, Preininger A, Mohr G, Siekmann J, Turecek P, Schwarz HP, Dorner F: Herstellung und Charakterisierung von rekombinantem Willebrand-Faktor, in Scharrer I, Schramm W (eds): 26. Hämophilie-Symposion Hamburg 1995, Berlin, Germany, Springer Verlag, 1997, p 147
12. Brinkhous KM, Sigman JL, Read MS, Stewart PF, McCarthy KP, Timony GA, Leppanen SD, Rup BJ, Keith JC, Garzone PD, Schaub RG: Recombinant human factor IX: Replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 88:2603, 1996
13. Giles AR, Tinlin S, Hoogendoorn H, Fournel MA, Nguyen P, Pancham N: In vivo characterization of recombinant factor VIII in a canine model of hemophilia A (factor VIII deficiency). Blood 72:335, 1988
14. Stokol T, Parry BW, Mansell PD: Factor VIII activity in canine von Willebrand disease. Vet Clin Pathol 24:81, 1995
15. Bouma BN, Dodds WJ, van Mourik JA, Sixma JJ, Webster WP: Infusion of human and canine factor VIII in dogs with von Willebrand's disease: Studies of the von Willebrand and factor VIII synthesis stimulating factors. Scand J Haematol 17:263, 1976
16. Brinkhous KM, Sandberg H, Garris JB, Mattsson C, Palm M, Griggs T, Read MS: Purified human factor VIII procoagulant protein: Comparative hemostatic response after infusions into hemophilic and von Willebrand disease dogs. Proc Natl Acad Sci USA 82:8752, 1985
17. Kraus KH, Johnson GS: Von Willebrand's disease in dogs. Curr Vet Ther 10:446, 1989
18. Brooks M: Management of canine von Willebrand's disease. Problems Vet Med (Transfusion Medicine) 4:636, 1992
19. Meyers KM, Wardrop KJ, Meinkoth J: Canine von Willebrand's Disease: Pathobiology, diagnosis, and short-term treatment. Comp Cont Ed 14:13, 1992
20. Authemem JM, Wolfsheimer KJ, Catchings S: Canine blood component therapy: Product preparation, storage, and administration. Am Anim Hosp Assoc 23:483, 1987
21. Stokol T: A study of von Willebrand disease in dogs in Australia. Doctoral thesis, University of Melbourne, Melbourne, Australia, 1993
22. Nichols TC, Bellinger DA, Reddick RL, Smith SV, Koch GG, Davis K, Sigman J, Brinkhous KM, Griggs TR, Read MS: The rotes of von Willebrand factor and factor VIII in arterial thrombosis: Studies in canine von Willebrand disease and hemophilia A. Blood 81:2644, 1993
23. Macfarlane DE, Stibbe J, Kirby EP, Zucker M, Grant RA, McPherson J: A method for assaying von Willebrand factor (Ristocetin Cofactor). Thromb Diathes Haemorrh 34:306, 1975
24. Evans RM, Austen DEC: Assay of ristocetin co-factor using fixed platelets and a platelet counting technique. Br J Haematol 37:289, 1977
25. Ruggeri ZM, Zimmerman TS: The complex multimeric composition of factor VIII/von Willebrand factor. Blood 57:1140, 1981
26. Aihara M, Sawada Y, Ueno K, Morimoto S, Yoshida Y, de Serres M, Cooper HA, Wagner RH: Visualization of von Willebrand factor multimers by immunoenzymatic stain using avidin-biotin peroxidase complex. Thromb Haemost 55:263, 1986
27. Austen DEC, Rhymes IL: A Laboratory Manual of Blood Coagulation, Oxford, UK, Blackwell Scientific, 1975
28. Lang H, Oberreither M, Moritz B: A new chromogenic factor VIII:C-assay based on a system of human proteins. Thromb Haemost 65:943, 1991 (abstr)
29. Sakariassen KS, Aarts PAMM, DeGroot PG, Houdijk WPM, Sixma JJ: A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix and purified components. J Lab Clin Med 102:522, 1983
30. Stel HV, Sakariassen KS, Scholte BJ, Veerman ECI, van der Kwast Th H, de Groot Ph G, Sixma JJ, van Mourik JA: Characterization of 25 monoclonal antibodies to factor VIII-von Willebrand factor: Relationship between ristocetin-induced platelet aggregation and platelet adherence to subendothelium. Blood 63:1408, 1984
31. Giles AR, Tinlin S, Greenwood R: A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood 60:727, 1982
32. Turecek PL, Gritsch H, Richter G, Auer W, Pichler L, Schwarz HP: Assessment of bleeding for the evaluation of therapeutic preparations in small animal models of anibody-induced hemophilia and von Willebrand disease. Thromb Haemost 77:591, 1997
33. Lee ML, Popovsky MA, Kingdon HS: A two-phase linear regression model for biologic half-life data. J Lab Clin Med 115:745, 1990
34. Slappendel RJ: Von Willebrand's disease in Dutch Kooiker dogs. Vet Q 17:521, 1995
35. Drouet L, Roussi J, Bonneau M, Pignaud GA, Turecek PL, Dorner F, Schlokat U, Falkner FG, Fischer B, Mitterer A, Schwarz HP: The effect of recombinant human von Willebrand factor in pigs with severe von Willebrand's disease. Blood 86:612a, 1995 (abstr, suppl 1)
36. Sodetz JM, Pizzo S, McKee P: Relationship of sialic acid to function and in vivo survival of human Factor VIII/von Willebrand factor protein. J Biol Chem 252:5538, 1977
37. Stoddart JH, Andersen J, Lynch DC: Clearance of normal and type 2A von Willebrand factor in the rat. Blood 88:1692, 1996
38. Fischer BE, Turecek PL, Mitterer A, Schlokat U, Falkner FG, Schwarz HP, Dorner F: Multimeric composition and structural analysis of a recombinant von Willebrand factor (rvWF). Thromb Haemost 73:1166, 1995 (abstr)
39. Furlan M, Robles R, Affolter D, Meyer D, Baillod P: Triplet structure of von Willebrand factor reflects proteolytic degradation of high molecular weight multimers. Proc Natl Acad Sci USA 90:7503, 1993
40. Furlan M, Robles R, Lämmle B: Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis. Blood 87:4223, 1996
41. Tsai HM: Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion. Blood 87:4235, 1996
42. Turecek PL, Furlan M, Lämmle B, Richter G, Gritsch H, Siekmann J, Schwarz HP: Cleavage of recombinant von Willebrand factor (vWF) by a vWF-depolymerizing protease. Blood 88:326a, 1996 (abstr, suppl 1)
43. Goudemand J, Mazurier C, Marey A, Caron C, Coupez B, Mizon P, Goudemand M: Clinical and biological evaluation in von Willebrand's disease of a von Willebrand factor concentrate with low factor VIII activity. Br J Haematol 80:214, 1992
44. Weiss HJ: Relation of von Willebrand factor to bleeding time. N Engl J Med ii:420, 1974 (letter)
45. Menache D, Aronson DL, Darr F, Montgomery RR, Gill JC, Kessler CM, Lusher JM, Phatak PD, Shapiro AD, Thompson AR, White GC: Pharmacokinetics of von Willebrand factor and factor VIIIC in patients with severe von Willebrand disease (type 3 vWD): Estimation of the rate of factor VIIIC synthesis. Br J Haematol 94:740, 1996